FOLD - Today's Research Reports on Trending Tickers: Amicus Therapeutics and Geron
NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed 1.19 percent to close at 24,688.31, while the S&P 500 Index decreased 1.73 percent to close at 2,658.69. The Nasdaq Composite Index dropped 2.06 percent to close at 7,167.21. For the week, the Dow Jones is down 3 percent, the S&P 500 and the Nasdaq lost 3.9 percent and 3.8 percent respectively.
According to Kelly Bogdanova, vice president of portfolio advisory group at RBC Wealth Management, “The market’s mood swings have been unsettling, but the underlying conditions that triggered the rout are unlikely to shatter the economic or earnings cycles. We think this will all sort out, but it will take some time.”
RDI Initiates Coverage on:
Amicus Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=FOLD
Geron Corporation
https://rdinvesting.com/news/?ticker=GERN
Amicus Therapeutics' stock jumped 5.57% Friday, to close the day at $11.57. The stock recorded a trading volume of 3,602,511 shares, which was above its three months average volume of 2,587,309 shares. In the last year, Amicus Therapeutics' shares have traded in a range of 10.33 - 17.62. The share price has gained 12% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $12.17 is below its 200-day moving average of $14.27. Shares of Amicus Therapeutics have fallen roughly 4.3 percent in the past month and are down 19.6 percent year-to-date.
Access RDI's Amicus Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FOLD
On Friday, shares of Geron recorded a trading volume of 2,524,742 shares, which was below the three months average volume of 8,820,828 shares. The stock ended the day 2.56% lower at $1.52. The share price has fallen 78.25% from its 52 week high with a 52 week trading range of 1.47 - 6.99. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.24 is below its 200-day moving average of $3.76. Shares of Geron have fallen roughly 13.64 percent in the past month and are down 15.56 percent year-to-date.
Access RDI's Geron Corporation Research Report at:
https://rdinvesting.com/news/?ticker=GERN
Our Actionable Research on Amicus Therapeutics, Inc. (NASDAQ :FOLD) and Geron Corporation (NASDAQ :GERN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com